Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23610934 | 0.93 | EHMT2 (0.41) | EHMT2EHMT1ITKPPARGSTING1 | |
| SCHEMBL23610930 | 0.88 | EHMT2 (0.44) | EHMT2EHMT1ITKPPARGSTING1 | |
| SCHEMBL23610925 | 0.88 | EHMT2 (0.41) | EHMT2EHMT1ITKPPARGSTING1 | |
| SCHEMBL21265770 | 0.86 | EHMT2 (0.42) | EHMT2EHMT1ITKPPARGSTING1 | |
| SCHEMBL30514376 | 0.85 | EHMT2 (0.41) | EHMT2EHMT1ITKPPARGSTING1 | |
| SCHEMBL23610933 | 0.82 | EHMT2 (0.48) | EHMT2EHMT1ITKSTING1PLK1 | |
| SCHEMBL21265768 | 0.81 | EHMT2 (0.42) | EHMT2EHMT1ITKPPARGSTING1 | |
| SCHEMBL21265863 | 0.81 | EHMT2 (0.45) | EHMT2EHMT1ITKPPARGSTING1 | |
| SCHEMBL30514369 | 0.81 | EHMT2 (0.45) | EHMT2EHMT1ITKPPARGSTING1 | |
| SCHEMBL23619385 | 0.79 | EHMT2 (0.41) | EHMT2EHMT1ITKSTING1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | CYP3A43, CYP3A4, CYP4B1 | EHMT2 3071/4885EHMT1 3461/4885ITK 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.